EconomyAstraZeneca says Hong Kong needs new funding model to attract global drugmakers
Hong Kong could draw more global biotech investment by developing a new healthcare financing model, AstraZeneca says. The pharmaceutical company has brought more than 60 clinical trials to the city and invested over HK$200 million in the past three years, while continuing to view Hong Kong as a key R&D hub.
S
South China Morning Post★★☆☆☆2026-10-01 08:00Original
AstraZeneca says Hong Kong needs new funding model to attract global drugmakers
Economy